ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 8094952

Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Willett CG and 4 others. Ann Surg, 1993. Cited by 339 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Papers, record 8094952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8094952

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.
PubMed
Journal
Ann Surg
PubMed
Year
1993
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
339
iCite
Relative citation ratio, by iCite
12
iCite
Revised in PubMed
2022-03-17
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Willett CGC G
2Lewandrowski KK
3Warshaw ALA L
4Efird JJ
5Compton CCC C

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Intraductal, NoninfiltratingMajor topic
PancreatectomyMajor topic
Pancreatic NeoplasmsMajor topic
PancreaticoduodenectomyMajor topic
Actuarial Analysis
Combined Modality Therapy
Female
Fluorouracil
Humans
Male
Middle Aged
Radiotherapy Dosage
Survival Analysis
Survival Rate

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03167112A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic CancerResults

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References8

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17,427,900Preoperative irradiation in carcinoma of the pancreas.Cancer1980https://conductscience.org/library/papers/7427900PubMed
24,015,380Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.Arch Surg1985https://conductscience.org/library/papers/4015380PubMed
32,461,172Pancreatic cancer in 1988. Possibilities and probabilities.Ann Surg1988https://conductscience.org/library/papers/2461172PubMed
42,016,628Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma.J Clin Oncol1991https://conductscience.org/library/papers/2016628PubMed
52,354,408Patterns of failure after curative resection of pancreatic carcinoma.Cancer1990https://conductscience.org/library/papers/2354408PubMed
61,987,845Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.Am J Surg1991https://conductscience.org/library/papers/1987845PubMed
71,824,810Implications of peritoneal cytology for staging of early pancreatic cancer.Am J Surg1991https://conductscience.org/library/papers/1824810PubMed
82,189,376Clinical and pathologic correlations in patients with periampullary tumors.Arch Surg1990https://conductscience.org/library/papers/2189376PubMed

Cited by86

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 339 citations.

PMIDTitleJournalYearIn PapersSource
40,935,440Intraoperative Radiation for Pancreatic Cancer.Semin Radiat Oncol2025https://conductscience.org/library/papers/40935440PubMed
40,304,947
Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with Pancreatic Ductal Adenocarcinoma: An Updated Multicenter Retrospective Cohort Study.
Ann Surg Oncol2025https://conductscience.org/library/papers/40304947PubMed
37,892,599
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
J Clin Med2023https://conductscience.org/library/papers/37892599PubMed
34,609,574Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy: A Meta-Analysis.World J Surg2022https://conductscience.org/library/papers/34609574PubMed
33,403,007A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.Ther Adv Med Oncol2020https://conductscience.org/library/papers/33403007PubMed
33,317,455Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.BMC Gastroenterol2020https://conductscience.org/library/papers/33317455PubMed
32,684,987Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?Ther Adv Med Oncol2020https://conductscience.org/library/papers/32684987PubMed
31,857,777
Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8th edition of the American Joint Committee on Cancer staging system.
World J Gastroenterol2019https://conductscience.org/library/papers/31857777PubMed
31,773,101SPECIFIC MOLECULAR RECOGNITION AS A STRATEGY TO DELINEATE TUMOR MARGIN USING TOPICALLY APPLIED FLUORESCENCE EMBEDDED NANOPARTICLES.Precis Nanomed2018https://conductscience.org/library/papers/31773101PubMed
31,650,262Clinical impact of additional therapy for residual pancreatic cancer.Surg Today2020https://conductscience.org/library/papers/31650262PubMed

1 to 10 of 86

See all 86 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs4

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
LEUCOVORIN CALCIUMCHEMBL1201138Results1https://conductscience.org/library/drugs/CHEMBL1201138ChEMBL
FLUOROURACILCHEMBL185Results1https://conductscience.org/library/drugs/CHEMBL185ChEMBL
OXALIPLATINCHEMBL414804Results1https://conductscience.org/library/drugs/CHEMBL414804ChEMBL
IRINOTECANCHEMBL481Results1https://conductscience.org/library/drugs/CHEMBL481ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8094952

GET https://conductscience.org/api/papers/v1/8094952/cited_by?page=2

API referenceFor AI assistants